RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice - Wikidata - wikimedia - TriplyDB

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice

http://www.wikidata.org/entity/Q33730699

about

Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice Targeted DNA mutagenesis for the cure of chronic viral infections Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives T-cell therapies for HIV Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS Novel approaches to inhibit HIV entry New generation humanized mice for virus research: comparative aspects and future prospects Hematopoietic-stem-cell-based gene therapy for HIV disease Achieving HIV-1 Control through RNA-Directed Gene Regulation Current prospects for RNA interference-based therapies Cell delivery of therapeutic nanoparticles Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice In vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis.Controlling the HIV/AIDS epidemic: current status and global challenges A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Molecular and Cellular Therapies: New challenges and opportunities.RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein.Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation.Riding in silence: a little snowboarding, a lot of small RNAs.Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.Chemokine receptor 5 knockout strategies.Stem cell-based anti-HIV gene therapy.Mice with human immune system components as in vivo models for infections with human pathogens.Ex vivo gene therapy for HIV-1 treatment.One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment.Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice RNA interference approaches for treatment of HIV-1 infection Generation of HIV latency in humanized BLT mice.Harnessing RNAi nanomedicine for precision therapy In vivo analysis of Nef's role in HIV-1 replication, systemic T cell activation and CD4(+) T cell loss.Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment.Nanotechnology and the treatment of HIV infection.BLT humanized mice as a small animal model of HIV infection.Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells.Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes.Progress on RNAi-based molecular medicines.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems

P2860

Q21133769-E964AA6D-2BD1-40EB-A3BE-9E521E5C7C8B Q24620150-82E56E39-FE25-44B3-B34C-ECD89DEEFC9B Q26777022-883861EC-AD6D-4440-85CF-CA3B046F132D Q26859021-94667A05-0DC9-4A26-BD1F-428A41CFF465 Q26866079-1C589471-2D66-4C82-A535-13F4ACECC8EA Q26866145-0B28035F-C28D-4063-B3F1-6892D2737DA3 Q27013957-A7F9FAF8-2D1A-42EC-B18C-F3EF4CFBDF23 Q27014786-FA8497A9-571A-451A-AE3F-275C40343AB4 Q27023434-49160C1A-D74D-42B6-B544-150E128DCDED Q28080090-E82A9356-A9CA-4F49-BEB8-828E2BB129D1 Q28235733-18F3D3E2-06F6-4D4D-B086-B962458236FB Q28385606-5925AD91-0C28-4723-A4AC-B5D0169F890C Q28488527-2434A415-BCF1-4EE7-A6C9-F400FE6C0FBA Q30009533-EB1BBEBF-B41C-4A6F-A408-AE0F9B0D84EA Q30420558-B685CD57-9B71-49A8-BD11-A595838D4D7C Q30431343-AE681C6D-8172-4562-A75F-54E6ED0D737A Q30488022-86B236B9-3451-4ACD-ACE1-47E835269A3F Q33565464-6E53A1F7-8932-4768-B806-1903F627140E Q33687594-955012EE-48DD-454E-9826-51B9F25D9C31 Q33777250-4DE72AE0-2977-4A46-962F-341D8C03A75D Q34474320-83D53DD1-DD17-4ED1-A871-EA155F221B1A Q34734219-E7E47649-52A2-420D-9993-6AA8C03644DD Q34769333-030A3040-0D77-49B2-A49B-11BBA4950FF7 Q34920166-3762497A-1D1A-4139-93D0-AD497E728892 Q34982851-75A82BE5-63D5-4863-B67F-35BB4CB5BD2E Q35140303-8894F283-7623-4027-9A08-D7D70DA0881D Q35144394-E56A8F71-1275-4E4D-B475-17573E6664F1 Q35206268-8917836D-38D4-4094-B68A-588CD6D9667B Q35623481-06E1759B-6C56-4FF1-9BDF-D326BF283977 Q35652119-85E7AFD9-476B-4AD5-8B2F-638DE7311000 Q35666126-96FF00C3-AFEB-4953-A681-FA7D2F6C6837 Q35673875-902CA47F-1F0A-43F2-9505-E0CE157947EB Q35848314-788C6132-2BAB-443B-8520-BC5732F39157 Q35876209-E219AA34-8DC0-4D59-9674-8E73B0C7EE4C Q35943647-4CC1C085-496E-4185-A4D5-FD358D8D1D61 Q35998374-2E4C0492-45B6-4F53-9385-C0E2C99EA603 Q36053809-1D00DF2E-CCAA-40E5-A394-986A6C752C12 Q36112824-036A0D7E-8E4B-484E-BFB1-6ED6BE3C9E30 Q36161380-1CD76160-01BB-4562-B075-2D179C1E73CF Q36341433-F4B9D65C-A293-42A8-ABC0-13D350BB42AD

P2860

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice

http://www.wikidata.org/entity/Q33730699

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice

@ast

RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice

@en

type

label

RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice

@ast

RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice

@en

prefLabel

RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice

@ast

RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice

@en

P1433

Q33730699-E7E30513-F332-4523-AA01-6AD077B88751

P1476

Q33730699-81B8D223-5D1D-4BB3-AAE2-9E0411A8E6F1

P2093

Q33730699-0190F656-6A8F-42BD-94F4-B5E27C63BFAC

Q33730699-4B243604-0D08-492B-B6E3-E6F33628F04E

Q33730699-85FB50AC-CBDE-460D-85EF-CEFF63F68077

Q33730699-888D6B21-95C0-41E5-9570-DAEF1DDE6D9A

Q33730699-B8EB7286-C467-4906-B38C-49F64B08241F

Q33730699-BF23BB47-3539-4D4B-AAD8-D4993D5E0839

Q33730699-E00AB433-C5A1-45A7-90D9-8460C5CF6077

Q33730699-FB034427-C229-4697-878D-7B3CF9756013

Q33730699-FC3D6AA0-CC4B-481F-BE98-8CC494F671F5

Q33730699-FE628302-51DA-47E3-B575-667AA02C395D

P2860

Q33730699-168086B3-B97F-4548-81A1-AA3C132B638D

Q33730699-213ED589-3702-4FEB-9C23-40476588C0D4

Q33730699-32011D70-7519-464C-A89D-644CD126834D

Q33730699-3787CDF7-2716-4F31-81CA-397F5250ED41

Q33730699-37E1A5DC-FBBA-4698-99F5-17B59C92F2D5

Q33730699-398E2704-95BF-497E-B16E-A1CA4C7EAD2A

Q33730699-4FCAF5BE-FBD9-4E3D-A54E-0A47E08C1CBD

Q33730699-54400269-D8B5-41EC-A61E-7605FFBF82E9

Q33730699-5A98B554-0AA2-4568-93D4-D46110B61B4D

Q33730699-5E412E9D-BC51-4E8C-8A94-D75BB9C374D4

P304

Q33730699-56C6B32C-8BF9-4BF9-83BF-67A290C1B8C8

P31

Q33730699-99863958-BED9-4584-A931-2E56085ADDEB

P356

Q33730699-28B62D7C-BB0E-4FC5-9AB0-077319BC7A96

P433

Q33730699-083186A5-F76A-47F7-88BD-E9B14AF30B49

P478

Q33730699-5A071293-9458-47F1-8176-59F2262DA249

P50

Q33730699-4A3203E7-A1E4-41A1-A843-5D01C0BB77B3

P577

Q33730699-75304A90-4838-4F10-915D-92D79C080148

P5875

Q33730699-50BEFADF-28FA-4121-A840-2BB829A0F956

P698

Q33730699-6ADAB8E6-52BC-4B89-8DDD-99988555D9AE

P921

Q33730699-C159D586-8D06-407C-89E2-F68F57E8FC25

P932

Q33730699-90791F25-3456-470E-B6EC-8FDF121C34F4

P356

P1433

Molecular Therapy

P1476

RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice

@en

P2093

Deshratan Asthana

http://www.w3.org/2001/XMLSchema#string

Huaquan Wu

http://www.w3.org/2001/XMLSchema#string

Katsuyoshi Habiro

http://www.w3.org/2001/XMLSchema#string

Motomu Shimaoka

http://www.w3.org/2001/XMLSchema#string

N Manjunath

http://www.w3.org/2001/XMLSchema#string

Premlata Shankar

http://www.w3.org/2001/XMLSchema#string

Priti Kumar

http://www.w3.org/2001/XMLSchema#string

Sandesh Subramanya

http://www.w3.org/2001/XMLSchema#string

Sang-Soo Kim

http://www.w3.org/2001/XMLSchema#string

Yong-Guang Yang

http://www.w3.org/2001/XMLSchema#string

P2860

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging

Asymmetry in the assembly of the RNAi enzyme complex

Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target

miRNA profiling of naïve, effector and memory CD8 T cells.

Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.

Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals

Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection.

HIV entry inhibitors and their potential in HIV therapy

Transvascular delivery of small interfering RNA to the central nervous system.

P304

370-376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.271

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40483905

http://www.w3.org/2001/XMLSchema#string

P698

19997090

http://www.w3.org/2001/XMLSchema#string

P921

P932

2839291

http://www.w3.org/2001/XMLSchema#string